FDA ApprovedUnited States
Infusion to Reduce Relapses in Childhood Nephrotic Syndrome
Gazyva (obinutuzumab) — infusion to reduce relapse risk in childhood-onset idiopathic nephrotic syndrome
FDA approved 25 Sep 2026 for ages 2 and older in complete remission; INShore NCT05627557
This is for families and adults living with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome who are in complete…